Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Stalevo 50)
7 results
  • Levodopa/carbidopa/entacapone in Parkinson's disease. [Journal Article]
    Expert Rev Neurother. 2009 Jul; 9(7):929-40.Seeberger LC, Hauser RA
  • Levodopa is the most efficacious agent for the treatment of motor features of Parkinson's disease but its chronic use is associated with the development of motor complications. Mounting evidence indicates the short half-life of levodopa and resultant pulsatile stimulation of striatal dopamine receptors leads to wearing off, motor fluctuations and dyskinesias. Longer acting dopaminergic agents, su…
  • Levodopa/carbidopa/entacapone (Stalevo). [Clinical Trial]
    Neurology. 2004 Jan 13; 62(1 Suppl 1):S64-71.Hauser RA
  • A levodopa/carbidopa/entacapone combination product (Stalevo) was recently approved to treat patients with idiopathic Parkinson's disease (PD) who experience end-of-dose "wearing-off." Stalevo is available in dose combinations of levodopa/carbidopa/entacapone 50/12.5/200 mg (Stalevo 50), 100/25/200 mg (Stalevo 100), and 150/37.5/200 mg (Stalevo 150). A series of pharmacokinetic studies demonstrat…
New Search